TABLE 1.
Immunization regimen and viral challenge
| Group | Vaccine(s)a | Animals subjected to SIVmac251 challengeb with:
|
|
|---|---|---|---|
| 10 IU i.v. | 20 MID50 i.r. | ||
| A | NYVAC–IL-12 | 279, 281, 282, 283 | 17604, 17633, 17697, 17701 |
| B | NYVAC-SIV | 268, 269, 270, 278 | 17427,c 17521, 17595, 17085 |
| C | NYVAC-SIV + NYVAC–IL-12 | 272, 273, 274, 275 | 17590, 17601, 17602, 17608 |
| D | NYVAC-SIV + NYVAC–IL-12 + NYVAC–IL-2 | 271, 276, 277, 280 | 17549, 17554, 17557, 17578 |
| E | NYVAC–IL-12 + NYVAC–IL-2 | 284, 285, 286, 287 | 17072, 17291, 17294, 17389 |
| F | NYVAC | 16794, 17547 | |
a
Each animal received the designated vaccine(s) at 0, 1, 6, and 12 months intramuscularly at a dose of 107 PFU.
b
The i.v. and i.r. challenge doses were given 6 and 9 months, respectively, after the last immunization.
c
This animal died during the early part of the study for reasons unrelated to the immunization regimen.